图书简介
This open access book focuses on the molecular mechanism of congenital heart disease and pulmonary hypertension, offering new insights into the development of pulmonary circulation and the ductus arteriosus. It describes in detail the molecular mechanisms involved in the development and morphogenesis of the heart, lungs and ductus arteriosus, covering a range of topics such as gene functions, growth factors, transcription factors and cellular interactions, as well as stem cell engineering technologies. The book also presents recent advances in our understanding of the molecular mechanism of lung development, pulmonary hypertension and molecular regulation of the ductus arteriosus. As such, it is an ideal resource for physicians, scientists and investigators interested in the latest findings on the origins of congenital heart disease and potential future therapies involving pulmonary circulation/hypertension and the ductus arteriosus.
PART I: Basic Science of Pulmonary Development and Pulmonary Arterial Disease.- 1Perspective for Part I.- 2 The alveolar stem cell niche of the mammalian lung.- 3 Lung development and Notch signalling.- 4 Specialized smooth muscle cell progenitors in pulmonary hypertension.- 5 Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension.- 6 Endothelial-to-mesenchymal transition in pulmonary hypertension.- 7 Extracellular vesicles, MicroRNAs and Pulmonary Hypertension.- 8 Roles of Tbx4 in the lung mesenchyme for airway and vascular development.- 9 A lacZ reporter transgenic mouse line revealing the development of pulmonary artery.- 10 Roles of stem cell antigen-1 in the pulmonary endothelium.- 11 Morphological characterization of pulmonary microvascular disease in bronchopulmonary dysplasia caused by hyperoxia in newborn mice.- 12 Involvement of CXCR4 and stem cells in a rat model of pulmonary arterial hypertension.- 13 Ca2+ signal through inositol trisphosphate receptors for cardiovascular development and pathophysiology of pulmonary arterial hypertension.- PART II: Abnormal pulmonary circulation in the developing lung and heart.- 14Perspective for Part II.- 15 Pathophysiology of Pulmonary Circulation in Congenital Heart Disease.- 16 Development of Novel Therapies for Pulmonary Hypertension by Clinical Application of Basic Research.- 17 Using Patient-Specific Induced Pluripotent Stem Cells to Understand and Treat Pulmonary Arterial Hypertension.- 18 Modeling pulmonary arterial hypertension using induced pluripotent stem cells.- 19 Dysfunction and restoration of endothelial cell communications in Pulmonary Arterial Hypertension: Therapeutic implications.- 20 Inflammatory Cytokines in the Pathogenesis of Pulmonary Arterial Hypertension.- 21 Genotypes and Phenotypes of Chinese Pediatric Patients with Idiopathic and Heritable Pulmonary Arterial Hypertension- Experiences from A Single Center.- 22 Fundamental Insight into Pulmonary Vascular Disease : Perspectives from Pediatric PAH in Japan.- 23 Risk stratification in paediatric pulmonary arterial hypertension.- 24 The Adaptive Right Ventricle in Eisenmenger Syndrome: Potential Therapeutic Targets for Pulmonary Hypertension.- 25 Impaired right coronary vasodilator function in pulmonary hypertensive rat assessed by in vivo synchrotron microangiography.- 26 Relationship between mutations in ENG and ALK1 gene and the affected organs in hereditary hemorrhagic telangiectasia.- 27 A genetic analysis for patients with pulmonary arterial hypertension.- 28 Evaluation and visualization of right ventricle using three dimensional echocardiography.- 29 Pulmonary hypertension associated with post-operative Tetralogy of Fallot.- 30 Microscopic Lung Airway Abnormality and Pulmonary Vascular Disease Associated with Congenital Systemic to Pulmonary Shunt.- 31 Respiratory syncytial virus infection in infants with heart and lung diseases.- PART III: Ductus arteriosus: bridge over troubled vessels.- 32Perspective for Part III.- 33 The ductus arteriosus, a vascular outsider, in relation to the pulmonary circulation.- 34 Molecular, genetic, and pharmacological modulation of the ductus arteriosus: KATP channels as novel drug targets.- 35 New mediators in the biology of the ductus arteriosus: Lessons from the chicken embryo.- 36 Constriction ofthe DuctusArteriosus with KATPChannelInhibitors.- 37 New insights on how to treat patent ductus arteriosus.- 38 Antenatal Administration of Betamethasone Contributes to Intimal thickening of the Ductus Arteriosus.- 39 Prostaglandin E-EP4-mediated fibulin-1 up-regulation plays a role in intimal thickening of the ductus arteriosus.- 40 Transcriptional profiles in the chicken ductus arteriosus during hatching.- 41 Inhibition of Cyclooxygenase Contracts Chicken Ductus Arteriosus.- 42 Prostaglandin E2 receptor EP4 inhibition constricts the rat ductus arteriosus.- 43 Dilatation of the Ductus Arteriosus by Diazoxide in Fetal and Neonatal Rats.- 44 The Effect of Long-term Administration of Plostaglandin E1 on Morphological Changes in Ductus Arteriosus.- 45 Significance of SGK1 as a protein kinase transcriptionally regulated by ALK1 signaling in vascular endothelial cells.- 46 Fabrication of Implantable Human Arterial Graft by Periodic Hydrostatic Pressure.- 47 Optimum preparation of Candida albicans cell wall extra (CAWE) for the mouse model of Kawasaki disease.- PART IV: Development and Regeneration of the Cardiovascular System.- 48Perspective for Part IV.- 49 Advances in the second heart field.- 50Novel cardiac progenitors for all components of the heart except for the right ventricle.- 51 Regional and TBX5-dependent gene expression in the atria: Implications for pulmonary vein development and atrial fibrillation.- 52 The Endocardium as a Master Regulator of Ventricular Trabeculation.- 53 The Role of Alternative mRNA Splicing in Heart Development.- 54 Progress in the Generation of Multiple Lineage Human-iPSC-derived 3D Engineered Cardiac Tissues for Cardiac Repair.- 55 Quantification of contractility in stem cell derived cardiomyocytes.- 56 A neurotrophic factor receptor GFRA2, a specific surface antigen for cardiac progenitor cells, regulates the process of myocardial compaction.- 57 Cardiac cell specification and differentiation by the defined factors.- 58A Temporo-Spatial Regulation of Sema3c is Essential for Interaction of Progenitor Cells during Cardiac Outflow Tract Development.- 59Spatiotemporally restricted developmental alterations in the anterior and secondary heart fields cause distinct conotruncal heart defects.- 60 Significance of transcription factors in the mechanisms of great artery malformations.- 61 The different c-kit expression in human induced pluripotent stem (iPS) cells between with feeder cells and without feeder cells.- 62 Establishment of induced pluripotent stem cells from immortalized B cell lines and their differentiation into cardiomyocytes.- 63Establishment of an in vitro LQT3 model, using induced pluripotent stem cells from LQT3 patient-derived cardiomyocytes.- 64 Genetic Assessments for clinical courses of Left ventricle noncompaction.- 65 Elucidating the pathogenesis of congenital heart disease in the era of next-generation sequencing.
Trade Policy 买家须知
- 关于产品:
- ● 正版保障:本网站隶属于中国国际图书贸易集团公司,确保所有图书都是100%正版。
- ● 环保纸张:进口图书大多使用的都是环保轻型张,颜色偏黄,重量比较轻。
- ● 毛边版:即书翻页的地方,故意做成了参差不齐的样子,一般为精装版,更具收藏价值。
关于退换货:
- 由于预订产品的特殊性,采购订单正式发订后,买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性,发生以下情况的,请直接拒收货物,由快递返回:
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全(例如:光盘等)
并请在工作日通过电话400-008-1110联系我们。
- 签收后,如发生以下情况,请在签收后的5个工作日内联系客服办理退换货:
- ● 缺页/错页/错印/脱线
关于发货时间:
- 一般情况下:
- ●【现货】 下单后48小时内由北京(库房)发出快递。
- ●【预订】【预售】下单后国外发货,到货时间预计5-8周左右,店铺默认中通快递,如需顺丰快递邮费到付。
- ● 需要开具发票的客户,发货时间可能在上述基础上再延后1-2个工作日(紧急发票需求,请联系010-68433105/3213);
- ● 如遇其他特殊原因,对发货时间有影响的,我们会第一时间在网站公告,敬请留意。
关于到货时间:
- 由于进口图书入境入库后,都是委托第三方快递发货,所以我们只能保证在规定时间内发出,但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间:
- 010-68433105/3213正常接听咨询电话的时间为:周一至周五上午8:30~下午5:00,周六、日及法定节假日休息,将无法接听来电,敬请谅解。
- 其它时间您也可以通过邮件联系我们:customer@readgo.cn,工作日会优先处理。
关于快递:
- ● 已付款订单:主要由中通、宅急送负责派送,订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐